背景:酒渣鼻是一种慢性炎症性皮肤病,主要表现为面部潮红,刺激,和痤疮。酒渣鼻和癌症被认为与炎症和免疫反应功能障碍的共性有关。研究这种可能的关联的研究报告了不同的结果。
目的:鉴于有关此主题的文献相互矛盾,我们的研究试图评估酒渣鼻与文献中常见的几种癌症之间的总体关联.
方法:使用Cochrane进行了系统评价,PubMed,Embase,Ovid数据库研究独立筛选酒渣鼻和神经胶质瘤和乳腺,甲状腺,肝,或皮肤癌。利用文章中的信息,酒渣鼻和每种癌症都被归类为阳性,负,或不清楚的关联。
结果:我们的系统评价包括39项全文研究,调查酒渣鼻与各种恶性肿瘤之间的关联。在令人关注的恶性肿瘤中,41%(16/39)的研究报告与基底细胞癌有关,2个队列显示调整后的风险比(RR)为1.50(95%CI1.35-1.67)和0.72(95%CI0.56-0.93)。总的来说,33%(13/39)的研究报告与鳞状细胞癌有关,2个队列显示校正RR为1.4(95%CI1.02-1.93)和1.30(95%CI0.90-1.88)。总共有8%(3/39)的研究报告了乳腺癌和黑色素瘤之间的关联,乳腺癌队列显示调整后的RR为8.453(95%CI1.638-43.606),1.03(95%CI0.89-1.20),和1.36(95%CI1.18-1.58),黑色素瘤队列显示调整后的RR为1.10(95%CI0.95-1.27),0.63(95%CI0.47-0.85),和0.96(95%CI0.57-1.62)。总共有5%(2/39)的研究报告了非黑色素瘤皮肤癌之间的关联,肝癌,和甲状腺癌,非黑色素瘤皮肤癌队列显示调整后的RR为1.36(95%CI1.26-1.47)和2.66(95%CI1.53-4.61),肝癌队列显示调整后的RR为1.42(95%CI1.06-1.90)和1.32(95%CI0.89-1.95),和甲状腺癌队列显示调整后的RR为1.06(95%CI0.68-1.65)和1.59(95%CI1.07-2.36)。只有一个队列报告与神经胶质瘤有关,显示调整后的RR为1.36(95%CI1.18-1.58)。根据我们的审查,酒渣鼻患者在统计学上更可能患有非黑色素瘤皮肤癌,乳腺癌,还有神经胶质瘤.未发现酒渣鼻与黑素瘤基本上相关。由于结果相互矛盾,酒渣鼻与肝癌和甲状腺癌之间的关联尚不清楚。
结论:目前的文献表明,酒渣鼻与非黑色素瘤皮肤癌的几率增加显著相关,神经胶质瘤,和乳腺癌。酒渣鼻似乎与黑色素瘤无关。应进行进一步的研究以阐明甲状腺癌和肝癌与酒渣鼻之间的关联。
BACKGROUND: Rosacea is a chronic inflammatory skin condition that predominantly manifests as facial flushing, irritation, and acne. Rosacea and cancer are thought to be linked by the commonality of inflammatory and immune response dysfunction. Studies that have looked into this possible association have reported mixed results.
OBJECTIVE: Given the conflicting literature on this topic, our study sought to evaluate the overall association between rosacea and several cancers commonly investigated in the literature.
METHODS: A systematic
review was conducted using the Cochrane, PubMed, Embase, and Ovid databases. Studies were screened independently for inclusion of rosacea and glioma and breast, thyroid, hepatic, or skin cancers. Using information from the articles, rosacea and each cancer were categorized as having a positive, negative, or unclear association.
RESULTS: Our systematic
review included 39 full-text studies that investigated the association between rosacea and various malignancies. Among the malignancies of concern, 41% (16/39) of the studies reported an association with basal cell carcinoma, with 2 cohorts revealing an adjusted risk ratio (RR) of 1.50 (95% CI 1.35-1.67) and 0.72 (95% CI 0.56-0.93). In total, 33% (13/39) of the studies reported an association with squamous cell carcinoma, with 2 cohorts revealing an adjusted RR of 1.4 (95% CI 1.02-1.93) and 1.30 (95% CI 0.90-1.88). A total of 8% (3/39) of the studies reported an association between breast cancer and melanoma, with breast cancer cohorts revealing an adjusted RR of 8.453 (95% CI 1.638-43.606), 1.03 (95% CI 0.89-1.20), and 1.36 (95% CI 1.18-1.58) and melanoma cohorts revealing an adjusted RR of 1.10 (95% CI 0.95-1.27), 0.63 (95% CI 0.47-0.85), and 0.96 (95% CI 0.57-1.62). A total of 5% (2/39) of the studies reported an association among nonmelanoma skin cancers, hepatic cancer, and thyroid carcinomas, with nonmelanoma skin cancer cohorts revealing an adjusted RR of 1.36 (95% CI 1.26-1.47) and 2.66 (95% CI 1.53-4.61), hepatic cancer cohorts revealing an adjusted RR of 1.42 (95% CI 1.06-1.90) and 1.32 (95% CI 0.89-1.95), and thyroid carcinoma cohorts revealing an adjusted RR of 1.06 (95% CI 0.68-1.65) and 1.59 (95% CI 1.07-2.36). Only 1 cohort reported an association with glioma, revealing an adjusted RR of 1.36 (95% CI 1.18-1.58). According to our
review, patients with rosacea were statistically more likely to have nonmelanoma skin cancers, breast cancer, and glioma. Rosacea was not found to be substantially associated with melanoma. The associations between rosacea and hepatic and thyroid cancers were unclear because of conflicting results.
CONCLUSIONS: The current literature shows that rosacea is significantly associated with increased odds of nonmelanoma skin cancers, glioma, and breast cancer. Rosacea does not appear to be associated with melanoma. Further studies should be conducted to clarify the association between thyroid and hepatic cancers and rosacea.